Albireo Pharma (NASDAQ:ALBO) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a research note released on Wednesday, AnalystRatings.com reports. HC Wainwright currently has a $62.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Hess Midstream Partners from a hold rating to a sell rating in a research report on Tuesday, May 14th. William Blair reaffirmed an outperform rating on shares of Albireo Pharma in a research report on Thursday, May 9th. Cowen reaffirmed a market perform rating and set a $99.00 price target (up previously from $97.00) on shares of United Continental in a research report on Wednesday, April 17th. BidaskClub raised Viacom from a sell rating to a hold rating in a research report on Friday, July 5th. Finally, ValuEngine lowered Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Albireo Pharma presently has an average rating of Buy and an average target price of $54.25.

Shares of NASDAQ ALBO traded down $1.37 during mid-day trading on Wednesday, reaching $29.44. 100,659 shares of the company’s stock were exchanged, compared to its average volume of 51,289. The stock has a market capitalization of $372.97 million, a price-to-earnings ratio of -7.47 and a beta of 1.56. The firm’s fifty day moving average is $32.27. Albireo Pharma has a twelve month low of $19.10 and a twelve month high of $38.69.

Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.37) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $1.20 million. Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%. As a group, analysts predict that Albireo Pharma will post -5.99 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in ALBO. Rhumbline Advisers boosted its position in shares of Albireo Pharma by 40.2% in the fourth quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 3,743 shares during the last quarter. Prudential Financial Inc. boosted its position in shares of Albireo Pharma by 5.6% in the fourth quarter. Prudential Financial Inc. now owns 26,556 shares of the biopharmaceutical company’s stock worth $652,000 after acquiring an additional 1,404 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Albireo Pharma by 7.2% in the fourth quarter. Bank of New York Mellon Corp now owns 37,552 shares of the biopharmaceutical company’s stock worth $921,000 after acquiring an additional 2,529 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Albireo Pharma by 40.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 116,223 shares of the biopharmaceutical company’s stock worth $2,850,000 after acquiring an additional 33,390 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Albireo Pharma by 11.3% in the fourth quarter. Geode Capital Management LLC now owns 97,434 shares of the biopharmaceutical company’s stock worth $2,390,000 after acquiring an additional 9,922 shares during the last quarter. 70.41% of the stock is currently owned by institutional investors and hedge funds.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Further Reading: Accumulation/Distribution

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.